1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,550 | 6,800 | 09.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Akari Therapeutics Plc: Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing Strategic Partnership with WuXi XDC | 1 | GlobeNewswire (USA) | ||
| WUXI XDC Aktie jetzt für 0€ handeln | |||||
| Mi | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| Mi | WUXI XDC (02268): GRANT OF RESTRICTED SHARES UNDER THE 2024 SHARE SCHEME | 1 | HKEx | ||
| Mo | Akari Therapeutics slides 21% despite WuXi XDC backing its drug program | 2 | Seeking Alpha | ||
| Mo | Akari Therapeutics Partners with WuXi XDC to Accelerate Development of Novel PH1 Payload | 1 | Contract Pharma | ||
| Mo | Akari Therapeutics partners with WuXi XDC on ADC development | 2 | Investing.com | ||
| Mo | Akari Therapeutics Plc: Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing | 59 | GlobeNewswire (Europe) | TAMPA, Fla. and LONDON, April 06, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing... ► Artikel lesen | |
| 31.03. | WUXI XDC (02268): JOINT ANNOUNCEMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ALL ... | 2 | HKEx | ||
| 25.03. | G Sachs Drops WUXI XDC TP to $85.9 as 2026 Guidance in Line | 1 | AASTOCKS | ||
| 24.03. | WUXI XDC Advances 5% as 2025 NP Hikes 38.4% to RMB1.48B | 1 | AASTOCKS | ||
| 23.03. | WUXI XDC (02268): INSIDE INFORMATION 2025 ANNUAL RESULTS PRESENTATION | - | HKEx | ||
| 23.03. | WUXI XDC (02268): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | 1 | HKEx | ||
| 13.03. | WUXI XDC (02268): JOINT ANNOUNCEMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ALL ... | 8 | HKEx | ||
| 27.02. | WuXi XDC, Earendil Labs Partner to Accelerate the Development of ADCs | 1 | Contract Pharma | ||
| 27.02. | Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs | 2 | FierceBiotech | ||
| 27.02. | WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform | 349 | PR Newswire | SHANGHAI, Feb. 27, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization)... ► Artikel lesen | |
| 11.02. | WUXI XDC (02268): MAJOR TRANSACTION IN RELATION TO VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE ... | - | HKEx | ||
| 11.02. | WUXI XDC (02268): JOINT ANNOUNCEMENT DESPATCH OF COMPOSITE DOCUMENT RELATING TO VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED ... | 1 | HKEx | ||
| 11.02. | WUXI XDC (02268): PINK FORM OF OPTION OFFER ACCEPTANCE AND CANCELLATION OF SHARE OPTIONS GRANTED BY BIODLINK INTERNATIONAL COMPANY LIMITED | 1 | HKEx | ||
| 11.02. | WUXI XDC (02268): WHITE FORM OF SHARE OFFER ACCEPTANCE AND TRANSFER OF ORDINARY SHARE(S) IN THE ISSUED SHARE CAPITAL OF BIODLINK INTERNATIONAL COMPANY ... | 3 | HKEx |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 86,52 | +4,05 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| QIAGEN | 35,030 | -1,14 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ARCELLX | 114,80 | +0,01 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 18,050 | +5,31 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| ONCONETIX | 1,210 | 0,00 % | Onconetix, Inc.: Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson | ||
| AMYLYX PHARMACEUTICALS | 17,320 | +2,30 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 33,520 | +1,51 % | Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs | - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 -
- Phase 1 healthy adult trial... ► Artikel lesen | |
| BICARA THERAPEUTICS | 21,980 | +1,76 % | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | ||
| EVOTEC | 4,526 | -3,21 % | Evotec Aktie: 2 Euro oder 6 Euro - wohin geht es für die Biotech-Aktie? | Nach dem Absturz der Evotec Aktie an die 4-Euro-Marke läuft bei dem Biotech-Titel ein erneuter Versuch einer Bodenbildung. Die zentrale charttechnische Unterstützung hat sich diesmal im Kern bei 3,995/4... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,620 | +6,37 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| COGENT BIOSCIENCES | 37,330 | +1,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| IMMUNOVANT | 25,650 | +3,72 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 15,210 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones | Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended... ► Artikel lesen | |
| ERASCA | 17,360 | 0,00 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,940 | +1,44 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen |
WUXI XDC CAYMAN INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,77 % bei einem Aktienkurs von 6,550 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu WUXI XDC CAYMAN INC finden Sie auf Wallstreet Online.